The Sur1-Trpm4 Channel in Spinal Cord Injury

J Marc Simard1,2,*, Seung Kyoon Woo1, Bizhan Aarabi1 and Volodymyr Gerzanich1

1Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, USA
2Department of Pathology, University of Maryland School of Medicine, Baltimore, USA

Abstract

Spinal cord injury (SCI) is a major unsolved challenge in medicine. Impact trauma to the spinal cord shears blood vessels, causing an immediate ‘primary hemorrhage’. During the hours following trauma, the region of hemorrhage enlarges progressively, with delayed or ‘secondary hemorrhage’ adding to the primary hemorrhage, and effectively doubling its volume. The process responsible for the secondary hemorrhage that results in early expansion of the hemorrhagic lesion is termed ‘progressive hemorrhagic necrosis’ (PHN). PHN is a dynamic process of auto destruction whose molecular underpinnings are only now beginning to be elucidated. PHN results from the delayed, progressive, catastrophic failure of the structural integrity of capillaries. The resulting ‘capillary fragmentation’ is a unique, pathognomonic feature of PHN. Recent work has implicated the Sur1-Trpm4 channel that is newly upregulated in penumbral microvessels as being required for the development of PHN. Targeting the Sur1-Trpm4 channel by gene deletion, gene suppression, or pharmacological inhibition of either of the two channel subunits, Sur1 or Trpm4, yields exactly the same effects histologically and functionally, and exactly the same unique, pathognomonic phenotype – the prevention of capillary fragmentation. The potential advantage of inhibiting Sur1-Trpm4 channels using glibenclamide is a highly promising strategy for ameliorating the devastating sequelae of spinal cord trauma in humans.

Keywords: Spinal cord injury; Sur1-Trpm4 Channel; Glibenclamide; Rl1zuole

Introduction

Spinal cord injury (SCI) is a major unsolved challenge in medicine. Worldwide, the incidence of SCI ranges from 10 to 83 per million people per year, with half of these patients suffering a complete lesion and one-third becoming tetraplegic [1]. In the United States, 250,000 people live with SCI and 11,000 new cases are added yearly. At present, little can be done to undo or repair the initial damage to spinal cord tissues, but great hope lies in reducing secondary injury processes triggered by the trauma that increase the damage and worsen clinical outcome.

Impact trauma to the spinal cord shears blood vessels, causing an immediate ‘primary hemorrhage’. The volume of the primary hemorrhage is directly related to the severity of the impact [2]. Numerous secondary injury mechanisms are then initiated, on a time scale from seconds to days, with microvascular dysfunction and endothelial cell loss being among the earliest pathophysiologcal responses observed [3]. During the hours following trauma, the region of hemorrhage enlarges progressively, with delayed or ‘secondary hemorrhage’ adding to the primary hemorrhage, and effectively doubling its volume. The process responsible for the secondary hemorrhage that results in early expansion of the hemorrhagic lesion is termed ‘progressive hemorrhagic necrosis’ (PHN). PHN is a dynamic process of autodestruction whose molecular underpinnings are only now beginning to be elucidated.

PHN results from the delayed, progressive, catastrophic failure of the structural integrity of capillaries [4]. As capillaries in the vicinity of the lesion fail, numerous microhemorrhages (petechial hemorrhages) form and coalesce, resulting in hemorrhagic lesion expansion. This dynamic process wherein the hemorrhagic contusion enlarges progressively results in the autodestruction of spinal cord tissues [4-8]. PHN is particularly damaging because it expands the volume of neural tissue destroyed by the primary injury. The capillary dysfunction implicit with PHN causes tissue ischemia and hypoxia [9], and the extravasated blood resulting from PHN is toxic to CNS cells, especially to the myelin-forming oligodendrocytes of white matter [10], resulting in further injury to neural tissues due to oxidative stress, lipid peroxidation and inflammation. Together, these processes render PHN one of the most destructive mechanisms of secondary injury identified following trauma to the spinal cord.

Early lesion expansion due to PHN was described more than 4 decades ago in an animal model of SCI [11], but has not been well characterized in humans, due largely to the enormous medical and technical challenges that are incurred when performing magnetic resonance imaging (MRI) on severely injured, often medically unstable patients early after trauma. Notwithstanding such difficulties, emerging evidence supports the concept of lesion expansion in humans with SCI [12,13], making this mechanism of secondary injury highly relevant clinically. The importance of these observations lies in the hope that, if early expansion of the hemorrhagic lesion can be halted, patients with acute SCI may suffer the least overall injury.

Progressive Hemorrhagic Necrosis – A Unique Phenotype of Capillary Fragmentation

Early lesion expansion

Histological and MRI studies on animal models of SCI have shown that early expansion of a hemorrhagic contusion is a common feature following trauma to the spinal cord. To our knowledge, the earliest study (weight drop; midline, lower thoracic / upper lumbar) quantifying early lesion expansion reported that, on H&E-stained sections, intramedullary hemorrhages involved an aggregate of 11% of the spinal cord area at the level of maximal bleeding immediately after trauma, and that this increased 2.5-fold to 28% after 8 hr [11]. In our previous study (weight drop; lateral C7), we reported a 2-fold increase
in the amount of extravasated blood in tissues from the epicenter during the first 12 hr after trauma [4]. In an MRI study (0.5 mm compression for 30 msec; T7), the T2 lesion volume was found to expand~1.5-fold over 5.5 hr [14]. In our recent study (weight drop; lateral C7) based on MRI T2 lesion volumes and measurements of hemorrhagic lesion areas, we found a 2–2.5-fold increase in the hemorrhagic contusion that takes place during the first 24 hr after blunt impact trauma to the spinal cord [15].

Together, the animal studies from different laboratories and from different epochs, using different methods to induce trauma, and different approaches to document lesion expansion, establish the existence of significant lesion expansion during the early hours after blunt impact trauma to the spinal cord.

**Capillary fragmentation**

The secondary hemorrhage that develops following the trauma arises from individual, discrete microscopic (petechial) hemorrhages that appear first near the site of injury then in more distant areas rostrally and caudally, mostly in the gray matter [4,16]. As microscopic hemorrhages form and coalesce, the lesion gradually expands, with a characteristic region of hemorrhage that ‘caps’ the advancing front of the lesion [6,8]. A small hemorrhagic lesion that initially involves primarily the capillary-rich gray matter enlarges several-fold during 3–24 hr after injury (Figure 1A) [11,17].

The formation of discrete microscopic hemorrhages is linked to the delayed progressive catastrophic failure of the structural integrity of capillaries. In static histological tissue sections, vimentin- or CD-31-positive capillaries appear foreshortened, as small segments of nearly the same length and width, a phenomenon termed ‘capillary fragmentation’ (Figure 2A) [4,18-20]. In some cases, including in humans (Figure 1B), extravasated erythrocytes are observed near microvessels that appear broken [19]. The presence of fragmented capillaries in the penumbra of injury is a pathognomonic feature of PHN. As discussed below, when the molecular antecedent of PHN is blocked, capillary fragmentation is absent (Figure 2B, 2C, 2D), early expansion of the hemorrhagic lesion is halted, and secondary hemorrhage is prevented, i.e., the volume of extravasated blood measured at 24 hr is nearly the same as in the primary hemorrhage, measured 15 min after trauma (Figure 1A) [4,15].

**Expression of the Sur1-Trpm4 channel in SCI**

Accumulating evidence indicates that the molecular antecedent of PHN is the Sur1-Trpm4 channel. This ion channel is not expressed constitutively, but is transcriptionally upregulated in endothelial and other cells after spinal cord trauma. In mice, rats and humans, upregulation of the regulatory subunit of the channel, Sur1 protein and its mRNA (Abcc8), has been demonstrated in microvessels, neurons and white matter using immunohistochemistry, immunoblot analysis,
and in situ hybridization [4,19,21]. In mice and rats, upregulation of the pore forming subunit of the channel, Trpm4 protein and its mRNA (Trpm4), has been shown in microvessels and neurons using immunohistochemistry, quantitative RT-PCR and in situ hybridization [18,21].

Co-association of the regulatory and pore-forming subunits to form functional Sur1-Trpm4 channels recently was shown using Förster resonance energy transfer (FRET) imaging microscopy and co-immunoprecipitation [21]. Antibody-based FRET was used to evaluate rat spinal cord tissues before and after injury. In uninjured spinal cord, Sur1 and Trpm4 immunolabeling was minimal [4,18,19], and FRET signals were absent. However, 24 hours after spinal cord trauma, Sur1 and Trpm4 immunolabeling was prominent, immunolabeling for Sur1 and Trpm4 co-localized, and FRET signals were detected in various cellular structures, including microvessels (Figure 3A).

In the same report [21], co-immunoprecipitation experiments showed abundant Sur1 and Trpm4 after spinal cord trauma. Co-immunoprecipitation using anti-Trpm4 antibody yielded Sur1, and co-immunoprecipitation using anti-Sur1 antibody yielded Trpm4. Importantly, communoprecipitation using anti-Sur1 antibody yielded Trpm4 only after spinal cord injury, not in uninjured spinal cord (Figure 3B). Together, these findings with co-immunoprecipitation and FRET demonstrate that Sur1 and Trpm4 co-assemble in vivo to form functional Sur1-Trpm4 channels following spinal cord injury.

**Progressive hemorrhagic necrosis – role of the Sur1-Trpm4 channel**

Various cell types exhibit de novo upregulation of Sur1-Trpm4 channels after spinal cord trauma, but secondary hemorrhage due to PHN is linked specifically to channel upregulation in microvessels [4,18,19]. Sur1-Trpm4 channels have been shown to be responsible for the necrotic death of endothelial cells that results in delayed fragmentation of capillaries and formation of microhemorrhages.

Evidence for involvement of the Sur1-Trpm4 channel in PHN comes from an analysis of the effects of gene deletion, gene suppression, or pharmacological inhibition of the two channel subunits, Sur1 and Trpm4. Remarkably, interfering with the function of either of the two channel subunits yields exactly the same effect histologically and functionally.

The phenotype observed after spinal cord injury in Abcc8−/− mice is exactly the same as in Trpm4−/− mice [18,19]. Both genotypes show the same post-SCI phenotype, and both are equally protected from PHN. Both genotypes show minimal secondary hemorrhage and lesion expansion, and the absence of capillary fragmentation, the hallmark of PHN. In a model of unilateral trauma (T9), functional outcomes, measured using the Basso mouse scale, and lesion volumes at 1 week are significantly better in both knockout mice compared to wild type mice.

Similarly, the phenotype observed after spinal cord injury in rats administered antisense oligodeoxynucleotide (AS-ODN) targeting Abcc8 is exactly the same as in rats administered AS-ODN targeting Trpm4. Both show the same phenotype, and both are equally protected from PHN. Both show minimal secondary hemorrhage and lesion expansion, and the absence of capillary fragmentation, the hallmark of PHN. In a model of unilateral trauma (C7), functional outcomes, measured using the Basso, Beattie, Bresnahan scale, and lesion volumes at 6 weeks are significantly better in rats administered either AS-ODN compared to rats administered scrambled ODN.

**Pharmacological blockade of Sur1**

Pharmacological blockade of Sur1 has been studied using two highly selective agents, glibenclamide and repaglinide [4]. Glibenclamide is a second generation sulfonylurea drug that binds to Sur1 with subnanomolar or nanomolar affinity (0.4–4.0 nM) [22] and potently inhibits the Sur1-Trpm4 channel (EC50 = 48 nM) [21,23]. Repaglinide is a member of a distinct class of insulin secretagogues that are structurally unrelated to sulphonylureas and whose binding site on Sur1 may differ from that of sulfonylureas [24]. Like glibenclamide, repaglinide produces high-affinity block of both native and recombinant β-cell KATP channels (IC50 = 0.9–7 nM), and shows higher potency in inhibiting pancreatic Sur1-regulated KATP channels than cardiovascular Sur2-regulated channels [25].
In rat models of SCI, glibenclamide and regapaglind exert beneficial effects that exhibit the signature features of inhibition of PHN. Rats treated with either glibenclamide or regapaglind show minimal secondary hemorrhage and lesion expansion, and the absence of capillary fragmentation, the hallmark of PHN (Figure 2C,2D). In models of unilateral or bilateral trauma (C7), functional outcomes, measured using the Basso, Beattie, Bresnahan scale, and lesion volumes at 6 weeks are significantly better in rats administered either compound, compared to controls [4,26]. Notably, direct comparison between glibenclamide and AS-ODN directed against Abcc8 shows equivalent effects in rats, in terms of functional outcomes and lesion volumes at 6 weeks, with neither compound exhibiting any observable toxicity [19].

In 4 separate series on rats from our laboratory [4,15,19,26], and in one series from an independent laboratory [27], glibenclamide treatment beginning shortly after trauma was found to be highly effective in reducing lesion size and improving neurological function. In a 6th series of rats, treatment at the clinically more relevant time of 3 hr after trauma also was found to be highly beneficial [20]. As might be expected, the magnitude of the benefit observed with glibenclamide depends on the magnitude of the primary injury [26], but all studies to date examining functional outcome and lesion size at 6 weeks have demonstrated a significant treatment effect, regardless of the initial severity [19,20,26].

**Pharmacological blockade of Trpm4**

At present, specific pharmacological blockade of Trpm4 is not feasible, possibly because of structural similarities of Trpm4 to other ion channels. Drugs that block Trpm4 are pleotropic, affecting other molecular targets. To date, pharmacological blockade of Trpm4 in SCI models has been pursued using flufenamic acid or riluzole. Flufenamic acid is an open-channel blocker of Trpm4 and of numerous other nonselective cationic channels, a widely expressed, heterogeneous family of channels of diverse molecular origins [28]. The benzothiazole, riluzole, recently was shown to block Trpm4 currents (IC50 = 31 µM) [20], but it also blocks other molecules. Riluzole was first proposed to inhibit glutamate release [29-32], thus protecting neurons from excitotoxic damage [33,34]. At micromolar concentrations (IC50, 3–10 µM), riluzole is considered to be a relatively selective blocker of ‘persistent sodium currents’ in cardiac myocytes and CNS neurons, including spinal cord neurons, where the molecular identity of the channel(s) responsible for these currents is not known [35-40]. Riluzole blocks several molecularly identified potassium channels [46-50], and calcium channels [51-53]. Riluzole also inhibits glutamate release [29,30,32], and it interacts with γ-aminobutyric acid A and glycine receptor-activated channels [30,54-56]. Riluzole also directly binds to and inhibits protein kinase C [57]. The role of any of these molecular targets in PHN is not known. It is possible that riluzole exerts part of its salutary effects via one these mechanisms, in addition to Sur1-Trpm4 inhibition, but specific involvement of any of these mechanisms has not been shown. Notably, involvement of glutamate antagonism is now thought to be unlikely [58,59].

A high degree of non-specificity in a drug generally is undesirable, since this can lead to untoward side-effects and undue toxicity. Non-specificity may account for the acute toxicity observed with high doses of riluzole, which includes somnolence, coma or a moribund state [60,61]. In addition, riluzole exhibits an unusual, dose-limiting CNS toxicity that is present only in CNS trauma, not in uninjured controls: mortality rates of 0%, 8% and 70% are observed with 4, 6 and 8 mg/kg IP every 12 hr × 1 week) starting 3 hr after trauma [20]. This study found that glibenclamide is superior to riluzole in terms of both toxicity and efficacy. During the acute phase after trauma, both drugs reduced capillary fragmentation and PHN (Figure 2), and both prevented death. At 6 weeks, modified (unilateral) Basso, Beattie, Bresnahan locomotor scores were similar, but measures of complex function (grip strength, rearing, accelerating rotarod) and tissue sparing were significantly better with glibenclamide than with riluzole. Note that in this preclinical study, riluzole was administered parenterally, which yields better bioavailability than enteral administration, and it was administered at a higher dose (on a ‘per kilogram’ basis), compared to the dose proposed for the anticipated clinical trial.

Apart from inhibiting PHN via blockade of Sur1-Trpm4, riluzole exerts other biological effects. At micromolar concentrations (IC50, 3–10 µM), riluzole blocks ‘persistent sodium currents’ in cardiac myocytes and CNS neurons, including spinal cord neurons, where the molecular identity of the channel(s) responsible for these currents is not known [35-40]. Riluzole blocks several molecularly identified potassium channels [46-50], and calcium channels [51-53]. Riluzole also inhibits glutamate release [29,30,32], and it interacts with γ-aminobutyric acid A and glycine receptor-activated channels [30,54-56]. Riluzole also directly binds to and inhibits protein kinase C [57]. The role of any of these molecular targets in PHN is not known. It is possible that riluzole exerts part of its salutary effects via one these mechanisms, in addition to Sur1-Trpm4 inhibition, but specific involvement of any of these mechanisms has not been shown. Notably, involvement of glutamate antagonism is now thought to be unlikely [58,59].

A high degree of non-specificity in a drug generally is undesirable, since this can lead to untoward side-effects and undue toxicity. Non-specificity may account for the acute toxicity observed with high doses of riluzole, which includes somnolence, coma or a moribund state [60,61]. In addition, riluzole exhibits an unusual, dose-limiting CNS toxicity that is present only in CNS trauma, not in uninjured controls: mortality rates of 0%, 8% and 70% are observed with 4, 6 and 8 mg/kg IP every 12 hr, respectively, in rats after SCI, whereas these doses are well tolerated in normal uninjured rats [44].

Drug specificity is less problematic with glibenclamide. Apart from high-potency block of Sur1-Trpm4 channels (EC50 = 48 nM) [21,23], glibenclamide also blocks Sur1-regulated KATP channels in pancreatic β cells [62]. However, at the doses used in CNS ischemia and trauma, the potential consequence of block of pancreatic KATP channels – hypoglycemia – is not observed; infusion of 200 ng/hr of glibenclamide in rats has a minimal effect on serum glucose [4,63,64]. Sur2-regulated KATP channels in cardiac and smooth muscle cells are less sensitive to block by glibenclamide, by a factor of 10 times or more [62,65].

**Glibenclamide vs. riluzole**

Riluzole has been found to be efficacious in preclinical models of SCI [20,43,44], may have a beneficial effect on motor outcome in cervical SCI, as recently reported in a small open-label Phase I clinical trial [45], and currently is the only drug that is anticipated for study in a Phase II clinical trial of acute SCI (Clinical Trials.gov identifier, NCT01597518). In the anticipated clinical trial, riluzole will be administered enterally at a dose of 2 × 100 mg the first 24 hours followed by 2 × 50 mg for the following 13 days after injury.

A recent preclinical study using a rat model of SCI, which was so severe as to have attendant mortality, compared treatment with riluzole (2.5 mg/kg IP every 12 hr × 1 week) vs. glibenclamide (10 µg/kg IP loading dose plus 200 ng/hr continuous subcutaneous infusion × 1 week), starting 3 hr after trauma [20]. This study found that glibenclamide is superior to riluzole in terms of both toxicity and efficacy. During the acute phase after trauma, both drugs reduced capillary fragmentation and PHN (Figure 2), and both prevented death. At 6 weeks, modified (unilateral) Basso, Beattie, Bresnahan locomotor scores were similar, but measures of complex function (grip strength, rearing, accelerating rotarod) and tissue sparing were significantly better with glibenclamide than with riluzole. Note that in this preclinical study, riluzole was administered parenterally, which yields better bioavailability than enteral administration, and it was administered at a higher dose (on a ‘per kilogram’ basis), compared to the dose proposed for the anticipated clinical trial.
Other ATP-binding cassette proteins of the ABC gene family may be blocked by glibenclamide, but only at micromolar concentrations [66], far greater than the concentrations achieved with infusion of 200 ng/hr in rats.

In the 6 series of rats reported to date on glibenclamide in SCI (see above), the drug was delivered by constant subcutaneous infusion. From a pharmacokinetic perspective, cutaneous delivery of glibenclamide is highly effective for maintaining steady plasma levels, is superior to enteral administration, and appears to be equivalent to intravenous (IV) administration [67]. Constant subcutaneous infusion of glibenclamide was used in the preclinical studies as a convenient alternative to constant IV infusion, as is used with injectable glibenclamide (RP-1127) in clinical trials for other CNS indications (ClinicalTrials.gov identifiers: NCT01454154; NCT01268683; NCT01794182). In the animal studies, no clinically relevant hypoglycemia or other toxicity has been detected with infusions of 200 ng/hr [4,63,64] or 400 ng/hr [68]. In a Phase I trial of RP-1127 in 16 normal subjects (ClinicalTrials.gov identifier: NCT01132703), a 3-day IV infusion (125 µg/hr) produced no clinically significant hypoglycemia or other serious adverse event (S. Jacobson, personal communication).

From the perspective of efficacy in targeting the Sur1-Trpm4 channel for reducing PHN, as well as from the perspective of safety and tolerability, glibenclamide may be a better choice than riluzole for the treatment of acute spinal cord injury.

Discussion

Each year, traumatic injury to the spinal cord devastates the lives of thousands of people worldwide. Short of preventing primary injury, the best hope for reducing the life-long impact of SCI rests with decreasing the secondary injury that results from PHN occurring during the acute phase after trauma. Although progress has been made in axonal and dendritic remodeling, cell replacement therapies, and rehabilitation, it is generally acknowledged that these treatments work best when administered to patients with the smallest possible lesion. To date, clinical trials with agents such as methylprednisolone (NASCIS 1) and IV glibenclamide (NASCIS 2) have demonstrated that treatments that are started within 8 hours of injury also improve outcomes. As reviewed here, emerging data indicate that in the earliest phase after trauma, the Sur1-Trpm4 channel is newly upregulated in the penumbra of injury, and that the expression of this channel in penumbral microvessels is integral to the subsequent development of PHN, which is responsible to early expansion of the hemorrhagic lesion. Also, as reviewed here, considerable data have now been published showing that targeting this channel by gene deletion, by lesion. Also, as reviewed here, considerable data have now been published showing that targeting this channel by gene deletion, by

In the 6 series of rats reported to date on glibenclamide in SCI (see above), the drug was delivered by constant subcutaneous infusion. From a pharmacokinetic perspective, cutaneous delivery of glibenclamide is highly effective for maintaining steady plasma levels, is superior to enteral administration, and appears to be equivalent to intravenous (IV) administration [67]. Constant subcutaneous infusion of glibenclamide was used in the preclinical studies as a convenient alternative to constant IV infusion, as is used with injectable glibenclamide (RP-1127) in clinical trials for other CNS indications (ClinicalTrials.gov identifiers: NCT01454154; NCT01268683; NCT01794182). In the animal studies, no clinically relevant hypoglycemia or other toxicity has been detected with infusions of 200 ng/hr [4,63,64] or 400 ng/hr [68]. In a Phase I trial of RP-1127 in 16 normal subjects (ClinicalTrials.gov identifier: NCT01132703), a 3-day IV infusion (125 µg/hr) produced no clinically significant hypoglycemia or other serious adverse event (S. Jacobson, personal communication).

From the perspective of efficacy in targeting the Sur1-Trpm4 channel for reducing PHN, as well as from the perspective of safety and tolerability, glibenclamide may be a better choice than riluzole for the treatment of acute spinal cord injury.

Conflicts of interest statement

JMS holds a US patent (#7,872,048), "Methods for treating spinal cord injury with a compound that inhibits a NC (Ca-ATP) channel ". JMS is a member of the scientific advisory board and holds shares in Remedy Pharmaceuticals. No support, direct or indirect, was provided to JMS, or for this project, by Remedy Pharmaceuticals. All other authors declare no conflict of interest.

References


